OSI Pharmaceuticals to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13, 2009
07 January 2009 - 2:00AM
Business Wire
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that Colin
Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals,
will present at the JP Morgan Conference in San Francisco, CA on
Tuesday, January 13, 2009 at 3:30 p.m. (Pacific Time). Dr. Goddard
will provide an overview on the Company�s product portfolio and
business developments. The presentation will be webcast live and
may be accessed by visiting OSI�s website at www.osip.com. A replay
of the webcast will also be available on the Company�s website
until January 27, 2009. About OSI Pharmaceuticals OSI
Pharmaceuticals is committed to "shaping medicine and changing
lives" by discovering, developing and commercializing high-quality
and novel pharmaceutical products designed to extend life and/or
improve the quality of life for patients with cancer and
diabetes/obesity. The Company�s oncology programs are focused on
developing molecular targeted therapies designed to change the
paradigm of cancer care. OSI�s diabetes/obesity efforts are
committed to the generation of novel, targeted therapies for the
treatment of type 2 diabetes and obesity. OSI's flagship product,
Tarceva� (erlotinib), is the first drug discovered and developed by
OSI to obtain FDA approval and the only EGFR inhibitor to have
demonstrated the ability to improve survival in both non-small cell
lung cancer and pancreatic cancer patients in certain settings. OSI
markets Tarceva through partnerships with Genentech, Inc. in the
United States and with Roche throughout the rest of the world. For
additional information about OSI, please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. Factors that might cause such
a difference include, among others, the completion of clinical
trials, the FDA review process and other governmental regulation,
OSI's and its collaborators' abilities to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, the ability to effectively market
products, and other factors described in OSI Pharmaceuticals'
filings with the Securities and Exchange Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More OSI Pharmaceuticals, Inc. News Articles